Amgen (AMGN) Reports Earnings Tomorrow: What To Expect — Apr 30th, 2025

Biotech company Amgen (NASDAQ:AMGN) will be reporting earnings tomorrow afternoon. Here’s what to expect. Amgen beat analysts’ revenue expectations by 2.6% last quarter, reporting revenues of $9.09 billion, up 10.9% year on year. It was a satisfactory quarter for the company, with ful...

S&P, Dow Pharma Stocks Boomerang On Drug-Pricing Order That Is 'All Bark' And 'Little Bite' — May 12th, 2025

Pharmaceutical stocks boomeranged Monday after Trump signed an executive order tying drug prices in the U.S. to international price tags. Continue Reading View Comments...

Stocks making big moves premarket: Shopify, AppLovin, Peloton, Tapestry and more — May 8th, 2025

Check out the companies making headlines in premarket trading. Shopify — Shares of the commerce technology platform dove 8.7% even after first-quarter revenue came in at $2.36 billion in revenue for the first quarter, beating the FactSet consensus estimate of $2.33 billion. Shopify had r...

Levi & Korsinsky Notifies Shareholders of Cerevel Therapeutics Holdings, Inc.(ABBV) of a Class Action Lawsuit and an Upcoming Deadline — May 8th, 2025

NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel Therapeutics Holdings, Inc." or the "Company") (NYSE: ABBV) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on...

If You Invested $10K In AbbVie Stock 10 Years Ago, How Much Would You Have Now? — May 7th, 2025

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. AbbVie Inc. (NYSE:ABBV), a biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. If You Bought...

ChatGPT Stock Advice: AbbVie Inc. (ABBV) Among Top Stock Recommendations — May 6th, 2025

We recently published a list of ChatGPT Stock Advice: Top 12 Stock Recommendations. In this article, we will take a look at where AbbVie Inc. (NYSE:ABBV) stands against other top stock recommendations by ChatGPT. After a two-year surge of 53%, the stock market has been taken for a wild ri...

S&P 500, Dow Jones Pharma Stocks Boomerang As Trump Threatens Drug-Price Reform — May 12th, 2025

Pharmaceutical stocks slipped Monday after Trump said he would sign an executive order to lower drug prices in the U.S. Continue Reading View Comments...

US-China trade truce, April CPI, drug prices: 3 Things — May 12th, 2025

US stock futures (ES=F, NQ=F, YM=F) are surging Monday morning after US and China officials agreed to significant cuts to each country's respective tariff rates in a 90-day cool-off period. April's Consumer Price Index (CPI) is due out tomorrow, reporting month-over-month trends in US inf...

Trump's drug price order is part request, part threat: Analyst — May 12th, 2025

President Trump signed an executive order on Monday calling for pharmaceutical companies to cut their drug prices for US consumers. Bernstein Senior Analyst, US Biopharmaceuticals Courtney Breen comments on whether the Trump administration ultimately has the power to force drug companies ...

1 Mega-Cap Stock Worth Your Attention and 2 to Keep Off Your Radar — May 6th, 2025

"Too big to fail" is how we would describe the megacap stocks in this article today. While they will likely stand the test of time, it’s not all sunshine and rainbows as their scale can limit their ability to find new sources of growth. These trade-offs can cause headaches for even the ...

If You Invested $10K In AbbVie Stock 10 Years Ago, How Much Would You Have Now? — May 7th, 2025

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. AbbVie Inc. (NYSE:ABBV), a biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. If You Bought...

Q1 Earnings Recap: AbbVie (NYSE:ABBV) Tops Therapeutics Stocks — May 8th, 2025

Let’s dig into the relative performance of AbbVie (NYSE:ABBV) and its peers as we unravel the now-completed Q1 therapeutics earnings season. Over the next few years, therapeutic companies, which develop a wide variety of treatments for diseases and disorders, face strong tailwinds from ...

Trump expected to sign order to slash US drug prices — May 12th, 2025

President Trump is expected to sign an executive order intended to cut US prescription drug prices in order to match drug prices overseas. Yahoo Finance senior health reporter Anjalee Khemlani outlines the many steps and government agencies involved in investigating and carrying out this ...

Levi & Korsinsky Reminds Cerevel Therapeutics Holdings, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 3, 2025 – ABBV — May 2nd, 2025

NEW YORK, May 02, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel Therapeutics Holdings, Inc." or the "Company") (NYSE: ABBV) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on...

Is AbbVie Inc. (ABBV) the Best Pharma Stock to Invest in Amid the Domestic Manufacturing Boom? — May 13th, 2025

We recently published a list of Domestic Manufacturing Boom: 12 Best Pharma Stocks to Invest in Now. In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against other best pharma stocks to invest in now amid the domestic manufacturing boom. Trump Incentivi...

JNJ vs. ABBV: Which Pharma Powerhouse Has Better Growth Prospects? — May 6th, 2025

Johnson & Johnson JNJ and AbbVie ABBV are two major U.S. pharmaceutical companies with robust pipelines and global operations. Both companies have a strong presence in immunology, oncology and neuroscience areas. Other than that, J&J also has drugs for cardiovascular and metabolic diseases...

IRWD Stock Down 15% as Q1 Earnings & Revenues Miss Estimates — May 8th, 2025

Ironwood Pharmaceuticals IRWD reported an adjusted loss of 14 cents per share for the first quarter of 2025, which was wider than the Zacks Consensus Estimate of a loss of 5 cents. The company had reported an adjusted loss of 2 cents per share in the year-ago quarter. Total revenues in th...

Why Investors Need to Take Advantage of These 2 Medical Stocks Now — Apr 29th, 2025

Two factors often determine stock prices in the long run: earnings and interest rates. Investors can't control the latter, but they can focus on a company's earnings results every quarter. Life and the stock market are both about expectations, and rising above what is expected is often re...

Amgen (AMGN) Reports Earnings Tomorrow: What To Expect — Apr 30th, 2025

Biotech company Amgen (NASDAQ:AMGN) will be reporting earnings tomorrow afternoon. Here’s what to expect. Amgen beat analysts’ revenue expectations by 2.6% last quarter, reporting revenues of $9.09 billion, up 10.9% year on year. It was a satisfactory quarter for the company, with ful...

1 Mega-Cap Stock Worth Your Attention and 2 to Keep Off Your Radar — May 6th, 2025

"Too big to fail" is how we would describe the megacap stocks in this article today. While they will likely stand the test of time, it’s not all sunshine and rainbows as their scale can limit their ability to find new sources of growth. These trade-offs can cause headaches for even the ...

Q1 Therapeutics Earnings: United Therapeutics (NASDAQ:UTHR) Impresses — May 14th, 2025

As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including United Therapeutics (NASDAQ:UTHR) and its peers. Over the next few years, therapeutic companies, which develop a wide variety of treatments for diseases and...

AbbVie Inc. (ABBV): Among the Best Income Stocks to Invest in Now — May 10th, 2025

We recently published a list of the Best Income Stocks to Invest in Now. In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against other best income stocks. Amid concerns over trade restrictions and a weakening economy, some investors are seeking stabili...

RINVOQ® (upadacitinib) Receives U.S. FDA Approval for Giant Cell Arteritis (GCA) — Apr 29th, 2025

– RINVOQ (upadacitinib) is now the first and only oral Janus Kinase (JAK) inhibitor approved for the treatment of GCA in adults – Also known as temporal arteritis, GCA is the most common vasculitis affecting adults in Western countries2 – This marks the ninth approved indication for...

Levi & Korsinsky Notifies Shareholders of Cerevel Therapeutics Holdings, Inc.(ABBV) of a Class Action Lawsuit and an Upcoming Deadline — May 13th, 2025

NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel Therapeutics Holdings, Inc." or the "Company") (NYSE: ABBV) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on...

AbbVie Stock: Using A Long-Term Leap Ratio Spread On This Pharma Giant — May 2nd, 2025

Positive post-earnings and a general upward draft of price action in the markets make for a strong argument for a bullish setup on AbbVie. Continue Reading View Comments...

Transforming HR Leadership: Inside The Darla Moore School’s Standout MHR Program — May 1st, 2025

CHRO of AbbVie Tim Richmond at the SC Moore School. Courtesy photo At the University of South Carolina’s Darla Moore School of Business, the Master of Human Resources (MHR) program is not just thriving—it’s setting the standard for excellence in HR education. With 100% job placement...

Cerevel Therapeutics Holdings, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before June 3, 2025 to Discuss Your Rights – ABBV — May 12th, 2025

NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV). Shareholders who purchased shares of ABBV during the class period listed are encouraged to contact the firm regarding possible l...

ChatGPT Stock Advice: AbbVie Inc. (ABBV) Among Top Stock Recommendations — May 6th, 2025

We recently published a list of ChatGPT Stock Advice: Top 12 Stock Recommendations. In this article, we will take a look at where AbbVie Inc. (NYSE:ABBV) stands against other top stock recommendations by ChatGPT. After a two-year surge of 53%, the stock market has been taken for a wild ri...

High Growth Tech Stocks In The US Market April 2025 — Apr 30th, 2025

The United States market has experienced a notable upswing, climbing 5.2% in the last week and showing a 9.9% increase over the past year, with earnings projected to grow by 14% annually in the coming years. In this dynamic environment, identifying high growth tech stocks involves focusing...

Moderna (MRNA) Reports Earnings Tomorrow: What To Expect — Apr 30th, 2025

Biotechnology company Moderna (NASDAQ:MRNA) will be announcing earnings results tomorrow before market hours. Here’s what you need to know. Moderna met analysts’ revenue expectations last quarter, reporting revenues of $966 million, down 65.6% year on year. It was a slower quarter for...

Biogen Earnings: What To Look For From BIIB — Apr 30th, 2025

Biotech company Biogen (NASDAQ:BIIB) will be announcing earnings results tomorrow before the bell. Here’s what you need to know. Biogen beat analysts’ revenue expectations by 1.8% last quarter, reporting revenues of $2.45 billion, up 2.9% year on year. It was a slower quarter for the ...

Biogen Earnings: What To Look For From BIIB — Apr 30th, 2025

Biotech company Biogen (NASDAQ:BIIB) will be announcing earnings results tomorrow before the bell. Here’s what you need to know. Biogen beat analysts’ revenue expectations by 1.8% last quarter, reporting revenues of $2.45 billion, up 2.9% year on year. It was a slower quarter for the ...

BOTOX® Cosmetic (onabotulinumtoxinA) Continues its Mission of Empowering Entrepreneurs Through "The Confidence Project" — May 1st, 2025

BOTOX® Cosmetic Will Provide 250 Entrepreneurs with Access to New Resources and Opportunities and Will Award 20 Grants Worth $20,000 Each to Support Business Goals. By 2030, BOTOX® Cosmetic Pledges to Empower 50,000 Entrepreneurs, Helping to Close the Confidence Gap. IRVINE, Calif., May...

How Trump could go about executing order to slash drug prices — May 12th, 2025

President Trump signed an executive order on Monday asking drugmakers to cut prices on their prescription drugs. Yahoo Finance consumer affairs reporter Jordan Weissmann reviews Trump's latest push to slash drug costs and how the administration may seek to go about it. To watch more expe...

The Zacks Analyst Blog Highlights Johnson & Johnson and AbbVie — May 7th, 2025

For Immediate Release Chicago, IL – May 7, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog inclu...

Q1 Earnings Recap: AbbVie (NYSE:ABBV) Tops Therapeutics Stocks — May 8th, 2025

Let’s dig into the relative performance of AbbVie (NYSE:ABBV) and its peers as we unravel the now-completed Q1 therapeutics earnings season. Over the next few years, therapeutic companies, which develop a wide variety of treatments for diseases and disorders, face strong tailwinds from ...

Q1 2025 Regenxbio Inc Earnings Call — May 13th, 2025

Participants Patrick Christmas; Chief Legal Officer; Regenxbio Inc Curran Simpson; President, Chief Executive Officer and Board Member; Regenxbio Inc Stephen Pakola; Executive Vice President, Chief Medical Officer; Regenxbio Inc Mitchell Chan; Chief Financial Officer; Regenxbio Inc Ma...

AbbVie Inc. (ABBV): A Bull Case Theory — May 7th, 2025

We came across a bullish thesis on AbbVie Inc. (ABBV) on Substack by Magnus Ofstad. In this article, we will summarize the bulls’ thesis on ABBV. AbbVie Inc. (ABBV)'s share was trading at $198.47 as of May 2nd. ABBV’s trailing and forward P/E were 84.82 and 16.34 respectively according...

AbbVie to Present at the Bank of America Securities Healthcare Conference — May 6th, 2025

NORTH CHICAGO, Ill., May 6, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Bank of America Securities Healthcare Conference on Wednesday, May 14, 2025. Management will participate in a fireside chat at 12:00 p.m. Central time. A live audio webcast of the presentation wil...

Class Action Filed Against Cerevel Therapeutics Holdings, Inc. (ABBV) - June 3, 2025 Deadline to Join – Contact The Gross Law Firm — May 1st, 2025

NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV). Shareholders who purchased shares of ABBV during the class period listed are encouraged to contact the firm regarding possible l...

Cerevel Therapeutics Holdings, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before June 3, 2025 to Discuss Your Rights – ABBV — May 5th, 2025

NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel Therapeutics Holdings, Inc." or the "Company") (NYSE: ABBV) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on...

What To Expect From BioMarin Pharmaceutical’s (BMRN) Q1 Earnings — Apr 30th, 2025

Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) will be reporting earnings tomorrow after the bell. Here’s what to look for. BioMarin Pharmaceutical beat analysts’ revenue expectations by 4.8% last quarter, reporting revenues of $747.3 million, up 15.6% year on year. It was a st...

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of June 3, 2025 in Cerevel Therapeutics Holdings, Inc. Lawsuit – ABBV — May 7th, 2025

NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV). Shareholders who purchased shares of ABBV during the class period listed are encouraged to contact the firm regarding possible l...

AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It — Apr 29th, 2025

AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over the past month, shares of this drugmaker have returned -8.2%, compared to the Zacks S&P 50...

Stocks making the biggest moves midday: AppLovin, Carvana, MercadoLibre, Crocs and more — May 8th, 2025

Check out the companies making headlines in midday trading. AppLovin — The mobile ad tech company jumped 12% after first-quarter results that beat analyst expectations. AppLovin also announced it would sell its mobile gaming business in a $400 million deal. Carvana — Shares jumped more...

AbbVie Inc. (ABBV): Among the Best Income Stocks to Invest in Now — May 10th, 2025

We recently published a list of the Best Income Stocks to Invest in Now. In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against other best income stocks. Amid concerns over trade restrictions and a weakening economy, some investors are seeking stabili...

Unpacking Q1 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) In The Context Of Other Therapeutics Stocks — May 9th, 2025

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q1, starting with Vertex Pharmaceuticals (NASDAQ:VRTX). Over the next few years, therapeutic companies, which develop ...

Trump Is Threatening Big Pharma With Tariffs. Tax Changes Might Work Better. — May 7th, 2025

No matter how high President Trump cranks up tariffs, many industries are never coming back to the U.S. For industries that require cheap labor such as apparel and toys, bringing that production to Pennsylvania or Ohio just doesn’t make sense. For pharma, an industry in which gross margi...

Drug Stocks Recover as Trump's Order Proves Not as Bad as Feared — May 13th, 2025

Shares of key drugmakers like Eli Lilly LLY, Pfizer PFE, Merck MRK, AbbVie ABBV, Gilead, Bristol-Myers, Amgen AMGN and several other U.S. pharmaceutical stocks were in the green at market close on Monday. The stocks recovered well from their pre-market decline on Monday in response to Pres...

What To Expect From BioMarin Pharmaceutical’s (BMRN) Q1 Earnings — Apr 30th, 2025

Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) will be reporting earnings tomorrow after the bell. Here’s what to look for. BioMarin Pharmaceutical beat analysts’ revenue expectations by 4.8% last quarter, reporting revenues of $747.3 million, up 15.6% year on year. It was a st...